Professor Jeremy Everett

Professor Jeremy Everett BSc, PhD, FRSC, CChem

Professor Jeremy Everett

Professor Jeremy R Everett
BSc, PhD, FRSC, CChem

Professor of Pharmaceutical Technologies

Department of Pharmaceutical, Chemical and Environmental Sciences

Faculty of Engineering and Science

Professor Jeremy Everett is Professor of Pharmaceutical Technologies in the Department of Pharmaceutical, Chemical & Environmental Sciences within the School of Science.

Professor Everett's main research focus is in metabolic profiling, also known as metabonomics or metabolomics. He has a particular interest in studying the consequences of genetic mutations on metabolic phenotypes and on the interplay between the genome and microbiome. He co-conceived, and named and defined metabonomics together with Professor Jeremy Nicholson (Imperial College, London), with whom he has a long-standing collaboration. He is a co-discoverer of pharmacometabonomics: which is the ability to predict the effects of drugs prior to dosing via metabolic profiling, and he is a co-inventor on a granted patent on pharmacometabonomics. He is a Visiting Professor in the Department of Surgery and Cancer at Imperial College. He is also currently the Acting Director of the Singapore Phenome Centre and is a scientific consultant and a Visiting Professor at the Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore.

Professor Everett is a co-leader of the Medway Metabonomics Group (MMRG) together with Dr Ruey-Leng Loo from the School of Pharmacy.

Professor Everett is the author of nearly 100 publications and reviews and a co-inventor on 3 patents. He has an H-index of 28 and has been cited in the literature over 4,000 times, with his top 4 papers each cited over 400 times.

Professor Everett consults for both major pharmaceutical and small biotech and research institutes on drug discovery. He is also a consultant for a New York law firm on pharmaceutical patents.

Prior to his current position, Professor Everett held a variety of drug discovery technology leadership positions at Pfizer, and before that, SmithKline Beecham and Beecham Research Laboratories. These positions included responsibilities for analytical sciences, automated purification, biobanking, chemoinformatics, computational chemistry, ligand-based drug design, curation, management and provision of the compound screening file, data support and management, lead generation by high throughput screening, compound library design and production, indications discovery, structural biology, structure-based drug design and drug target analysis.

Professor Everett received both his BSc in chemistry and PhD in physical organic chemistry from Nottingham University. He was a Post-doctoral Fellow at McMaster University in Hamilton, Ontario, and a Research Associate at McGill University, Montréal.

  • University representative to the Heads of Chemistry UK (HCUK) at the Royal Society of Chemistry

Course participation

  • Advanced Instrumental Analysis
  • Applied Plant Science
  • Chemometrics and Informatics
  • Computational Chemistry
  • Drug Discovery and Medicinal Chemistry
  • Medicinal Chemistry and Therapeutics
  • Open Course for Chemists
  • Pharmaceutics
  • Pharmaceutical Analysis & Testing
  • Pharmaceutical Product Development and Manufacture
  • Research and Professional Skills
  • Research Methods and Data Management
  • Special Topics in Chemistry

MPhil/PhD supervision

  • Mohamed Abdelghany
  • Dorna Varshavi
  • Fellow of the Royal Society of Chemistry (FRSC)
  • Chartered Chemist (CChem)
  • Visiting Professor, Department of Surgery and Cancer, Imperial College, London
  • Visiting Professor Lee Kong Chian School of Medicine, Nanyang Technological University
  • Member of the American Chemical Society
  • Fellow of the Higher Education Academy

Professor Jeremy Everett's research covers metabonomics, pharmacometabonomics, with a particular focus on the relationship between genetic mutation and metabolic phenotype. He has 100 publications and patents including two, landmark publications in PNAS and Nature on the discovery of pharmacometabonomics. Web of Science Impact Factor: h-index = 28, with over 4,000 citations.


  • Clayton, T.A., Everett, J.R., Lindon, J.C., and Nicholson, J.K. Metabolic Phenotyping. WO 03/107270 A2, published 24 December 2003
  • Everett, J. et al. Molecular Markers of Oxidative Stress. PC32039, filed November 2003 ACCESSION NUMBER:2005:493754 HCAPLUS PRIORITY APPLN. INFO.: GB 2003-27743 A20031128; US 2004-558937 P20040402.

, , , , , , , and () . In: Frontiers in Molecular Biosciences. Frontiers Media.

() . In: Progress in Nuclear Magnetic Resonance Spectroscopy. Elsevier. pp. 1-14. ISSN 0079-6565 ISSN 0079-6565

, and () . In: International Journal of Pharmacokinetics. pp. 5-8. ISSN 2053-0846 ISSN 2053-0846

, , , , , , , , and () . In: Molecular Diversity. Springer Verlag. pp. 789-803. ISSN 1381-1991 ISSN 1381-1991

() . In: Frontiers in Pharmacology. Frontiers Media S.A.. ISSN 1663-9812 ISSN 1663-9812

and () . In: Journal of Proteome Research. American Chemical Society. pp. 3405-3419. ISSN 1535-3893 ISSN 1535-3893

, , , , , and () . In: Computational and Structural Biotechnology Journal. Elsevier. pp. 135-153. ISSN 2001-0370 ISSN 2001-0370

() . In: Expert Opinion on Drug Discovery. Routledge Taylor & Francis. pp. 937-944. ISSN 1746-0441 ISSN 1746-0441

, , , , , , , , , , , and () . In: Biochemical Pharmacology. Elsevier Inc.. pp. 267-277. ISSN 0006-2952 ISSN 0006-2952

() . In: Pharmacogenomics. Future Medicine Ltd.. pp. 737-754. ISSN 1462-2416 ISSN 1462-2416

() . In: Computational and Structural Biotechnology Journal. Elsevier B.V.. pp. 131-144. ISSN 2001-0370 ISSN 2001-0370

, and () . In: Annals of Clinical Biochemistry. Royal Society of Medicine Press. pp. 523-545. ISSN 0004-5632 ISSN 0004-5632

, , , , , , , , , and () . In: Molecular Diversity. Springer Netherlands. pp. 319-335. ISSN 1381-1991 ISSN 1381-1991

() . In: Expert Opinion on Drug Discovery. Informa Plc. pp. 357-361. ISSN 1746-0441 ISSN 1746-0441

, , , , , , , , , and () . In: Journal of Chemical Information and Modeling. ACS Publications. pp. 2937-2949. ISSN 1549-9596 ISSN 1549-9596

, , , , , and () . In: Journal of Proteome Research. ACS Publications. pp. 4630-4642. ISSN 1535-3893 ISSN 1535-3893

, and () . In: Expert Opinion on Drug Metabolism & Toxicology. Informa Healthcare. pp. 135-139. ISSN 1742-5255 ISSN 1742-5255

Browse our research at GALA

() . In: The Handbook of Metabolic Phenotyping. Elsevier. pp. 407-448. ISBN 978-0128122938

, and () . In: Metabolic Phenotyping in Personalized and Public Healthcare. Elsevier Science Publishing Co Inc. pp. 137-165. ISBN 9780128003442

() . In: NMR in Pharmaceutical Sciences. John Wiley & Sons Ltd, Chichester, UK. pp. 359-372. ISBN 9780470034590

() . In: eMagRes. In: eMagRes. John Wiley & Sons, Ltd., London, UK. pp. 137-150. ISBN 9780470034590

Browse our research at GALA

, , and (Eds.) (2015) . Wiley. ISBN 9781118997666

Browse our research at GALA